Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cost effectiveness of lipid lowering therapy].

G Wendland1, G Klever-Deichert, K Lauterbach

  • 1Institut für Gesundheitsökonomie und klinische Epidemiologie, Köln. guido.wendland@medizin.uni-koeln.de

Herz
|February 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.

Diabetic medicine : a journal of the British Diabetic Association·2006
Same author

[Cost-effectiveness of prevention of coronary disease in Germany].

Zeitschrift fur Kardiologie·2005
Same author

Asthma: prevalence and cost of illness.

The European respiratory journal·2005
Same author

Using diagnosis-related groups. The situation in the United Kingdom National Health Service and in Germany.

The European journal of health economics : HEPAC : health economics in prevention and care·2004
Same author

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2004
Same author

[Prospective observation of abdominal ultrasound in radiological emergency services: approaches to cost saving].

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2003
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
Same journal

Relationship between HAVOC score and new-onset atrial fibrillation in patients with ST elevation myocardial infarction.

Herz·2026
Same journal

Interventional treatment of atrioventricular valves.

Herz·2026
See all related articles

Statins are cost-effective for secondary prevention of coronary heart disease (CHD). Their cost-effectiveness in primary prevention depends on individual CHD risk, with benefits seen at a 1.5% annual risk.

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Cardiovascular Disease Prevention

Context:

  • Increasing pressure for healthcare cost savings necessitates robust economic evaluations.
  • Lipid-lowering therapies, particularly statins, are crucial in managing cardiovascular health.
  • Methodological considerations significantly influence the interpretation of cost-effectiveness analyses.

Purpose:

  • To evaluate the cost-effectiveness of statin therapy in the prevention of coronary heart disease (CHD).
  • To compare the effectiveness of different lipid-lowering therapies, including non-pharmacological interventions and statins.
  • To determine the threshold for CHD risk at which statin therapy becomes both effective and efficient.

Summary:

  • Statins demonstrate cost-effectiveness in secondary prevention of CHD from a social insurance perspective.

Related Experiment Videos

  • In primary prevention, the cost-effectiveness of statins is contingent on the patient's initial CHD risk.
  • A yearly CHD risk of approximately 1.5% is identified as a threshold for cost-effective statin therapy.

    • Impact:

    • Provides evidence for healthcare decision-makers regarding the economic value of statin therapy.
    • Informs resource allocation in cardiovascular disease prevention strategies.
    • Highlights the importance of risk stratification in optimizing the use of lipid-lowering medications.